Cynata Therapeutics Limited is an Australian clinical-stage biotechnology company developing disruptive regenerative medicine products.
By using our unique manufacturing platform, Cymerus™, which enables us to economically produce therapeutic mesenchymal stem cells (MSCs) at scale with a consistent quality, we are able to overcome the inherent challenges in first generation methods of manufacturing MSCs for therapeutic use.
We have generated compelling preclinical data in models of a range of different therapeutic indications. We have completed a Phase I clinical study with our lead MSC product candidate, CYP-001, in the treatment of steroid-resistant graft-versus-host-disease, a disease with devastating results. The trial results demonstrated excellent safety and efficacy data, which allows us to progress to a Phase II study.
Our partner-centric business model potentially allows us to partner each target disease, maximising our revenue opportunities and ability to leverage the right expertise in the target indication. We are currently partnered with the Japanese-firm Fujifilm for our lead candidate, CYP-001. Fujifilm have a license option agreement over this product, which if exercised would require Fujifilm to pay a US$3m upfront licensing fee, followed by milestone payments of up to $60m and ultimately ongoing, double-digit royalty payments.